Daniel Abernathy, Director, Otsuka, McQuade Center for Strategic Research and Development
Daniel “Danny” Abernathy is a director in the McQuade Center for Strategic Research and Development (MSRD) a corporate venture capital entity within Otsuka which invests and partners with early-stage drug companies that align with the global strategic vision of Otsuka. Our goal is to search for, identify, and fund innovative early-stage research/development programs that have the potential to improve treatment for diseases and disorders of the CNS, Kidney and Immune System.
Danny’s drug development background spans from discovery through manufacturing, with a focus on leading preclinical and externally facing programs. Previously he has held scientific leadership roles at Landmark Bio, Takeda, and Tessera Therapeutics where he advanced novel platforms and programs into therapeutic development. He earned his PhD in Developmental, Regenerative, and Stem Cell Biology from Washington University in St. Louis, followed by postdoctoral research at Harvard.
